Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California. Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment offers a range of pharmaceutical products, including ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, and allergy; Botox for the therapeutic and aesthetic indications; skin care products for acne, psoriasis, and other skin care products; eyelash growth products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery; obesity intervention products, including the Lap-Band System and the BIB BioEnterics Intragastric Balloon; and facial aesthetics products.Allergan company also offers Contigen for the treatment of urinary incontinence due to intrinsic sphincter deficiency. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, and ambulatory surgery centers, as well as to medical practitioners, including ophthalmologists, neurologists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, pediatricians, urologists, and general practitioners. Allergan, Inc. has strategic research collaboration agreements with ExonHit Therapeutics S.A.; Spectrum Pharmaceuticals, Inc.; and Pieris AG.

Allon Therapeutics Inc. company's primary focus is on developing treatments for Alzheimer's and other neurodegenerative diseases that lead to memory loss and cognitive impairment. Its lead candidate AL-108 is a nasal spray that has shown some efficacy in clinical trials in treating the symptoms of patients with amnestic mild cognitive impairment, a precursor to Alzheimer's. Allon has collaborations with the National Institute on Aging, the Alzheimer's Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Palatin Technologies, Inc. company was founded in 1986 and is based in Cranbury, New Jersey. Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome.

Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

Orion shines brightly over Scandinavia. At the heart of the health care group is Orion Pharma, one of Finland's largest drug makers. Orion Pharma manufactures prescription, generic, and OTC pharmaceuticals, as well as veterinary medicines. Its Fermion subsidiary manufactures active pharmaceutical ingredients (API) for use by Orion and other drug makers. Orion company's research is focused on developing treatments for central nervous system, cardiovascular, and urological disorders, as well as cancer. Orion Diagnostica develops and manufactures diagnostic tests to be used on site in physicians' offices.

Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.

For biotechnology and pharmaceutical companies whose next big breakthrough is stuck in the test tube, Oxford Therapeutics Consulting could have the answer. The product development consulting firm offers strategic planning and product management for biotechs and pharmas that are short on staff and experience in bringing a new product through the lengthy development pipeline. Oxford Therapeutics' team of consultants work primarily with smaller companies on products such as anticancer agents, antibacterial and antiviral compounds, and therapeutic vaccines.

ZARS Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing topically administered drugs using its proprietary drug delivery technologies, primarily in the area of pain management. It is developing a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery and phase-changing cream technologies. The company’s products include Pliaglis, a topical anesthetic cream for dermal anesthesia prior to painful cosmetic procedures, such as laser surgery and dermal filler injections; and Synera, a topical patch for providing dermal analgesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Its products also comprise ThermoProfen, which is entering into Phase 3 clinical trials for the treatment of mild to moderate chronic pain associated with osteoarthritis of the knee; and Ketoprofen DuraPeel, a Phase 1 clinical trial product for the treatment of acute musculoskeletal pain resulting from soft tissue injuries, such as muscle strains, ankle sprains, and sports injuries. In addition, the company is developing the Alprazolam Patch, which is in Phase 1 clinical trial, for the treatment of panic disorder. The company was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July, 2007. The company was founded in 1996 and is based in Salt Lake City, Utah.

Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.